Literature DB >> 9683952

The use of corticosteroids for choroidal neovascularisation in young patients.

C J Flaxel1, S L Owens, B Mulholland, S D Schwartz, Z J Gregor.   

Abstract

PURPOSE: To investigate the role of systemic corticosteroids in the treatment of sight-threatening choroidal neovascularisation (CNV) in patients with punctate inner choroidopathy (PIC) and multifocal inner choroiditis (MIC).
METHODS: Twelve eyes of 10 patients with evidence of PIC or MIC with recent visual symptoms were identified. All eyes had CNV within the foveal avascular zone on fundus fluorescein angiography (FFA). Systemic oral prednisolone at an initial dose of 1 mg/kg (60-80 mg) was given for 3-5 days and the dose was subsequently tapered. Changes in best corrected visual acuity and leakage on FFA were recorded during follow-up. Systemic side-effects of the corticosteroids were monitored.
RESULTS: In 10 of 12 eyes vision improved or stabilised. Leakage on FFA resolved in 9 eyes and was reduced in 3. Four patients required more than one course of oral corticosteroids. One patient was maintained on low-dose oral corticosteroids for recurrent CNV activity. No systemic complications from the treatment were observed.
CONCLUSION: A course of oral corticosteroids in healthy young patients with subfoveal CNV in PIC or MIC may reduce subretinal vascular leakage and stabilise vision when no other proven treatment option is available.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683952     DOI: 10.1038/eye.1998.62

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  26 in total

1.  Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy.

Authors:  S Chatterjee; J M Gibson
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

2.  Sorsby fundus dystrophy presenting with choroidal neovascularisation showing good response to steroid treatment.

Authors:  D Atan; C Y Gregory Evans; D Louis; S M Downes
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

3.  Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation.

Authors:  A Hogan; U Behan; D J Kilmartin
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

4.  Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.

Authors:  Alfonso Giovannini; Piergiorgio Neri; Lucia Mercanti; Claudia Bruè
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

5.  The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients.

Authors:  C J Flaxel
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

Review 6.  Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment.

Authors:  Narendra Dhingra; Susan Kelly; Mohammed A Majid; Claire B Bailey; Andrew D Dick
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

7.  Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease.

Authors:  S R Nowilaty; M Bouhaimed
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

8.  Inflammatory choroidal neovascularization.

Authors:  Piergiorgi Neri; Marta Lettieri; Cinzia Fortuna; Mara Manoni; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

9.  Idiopathic choroidal neovascularisation as the inaugural sign of multiple evanescent white dot syndrome.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

10.  Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis.

Authors:  Thi Ha Chau Tran; Christine Fardeau; Céline Terrada; Ghislaine Ducos De Lahitte; Bahram Bodaghi; Phuc Lehoang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.